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Abstract
To understand how cytotoxic agent-induced cancer cell death affects the immune system is of fundamental importance to
stimulate immune response to counteract the high mortality due to cancer. Here we compared the immunogenicity of
Primary Effusion Lymphoma (PEL) cell death induced by anticancer drug Bortezomib (Velcade) and Tyrphostin AG 490, a
Janus Activated Kinase 2/signal trasducer and activator of transcription-3 (JAK2/STAT3) inhibitor. We show that both
treatments were able to induce PEL apoptosis with similar kinetics and promote dendritic cells (DC) maturation. The surface
expression of molecules involved in immune activation, namely calreticulin (CRT), heat shock proteins (HSP) 90 and 70
increased in dying cells. This was correlated with DC activation. We found that PEL cell death induced by Bortezomib was
more effective in inducing uptake by DC compared to AG 490 or combination of both drugs. However the DC activation
induced by all treatments was completely inhibited when these cells were pretreated with a neutralizing antiboby directed
against the HSP90/70 and CRT common receptor, CD91. The activation of DC by Bortezomib and AG 490 treated PEL cells,
as seen in the present study, might have important implications for a combined chemo and immunotherapy in such
patients.
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Introduction
Primary effusion lymphoma (PEL) is a non-Hodgkin’s lympho-
ma characterized by lymphomatous effusions of pleural, pericar-
dial and abdominal cavities [1]. It is characterized by a poor
response to conventional chemotherapy and by an extremely
aggressive clinical course. Its pathogenesis seems to be linked to an
oncogenic virus, human herpesvirus 8 (HHV-8, also called KSHV,
Kaposi’s sarcoma associated herpes virus) [2]. Promising prelim-
inary results in the PEL treatment have been obtained with
Bortezomib, a proteasome inhibitor known to induce caspase-
dependent apoptosis of PEL cells in vitro [3]. Bortezomib has
received Food and Drug Administration (FDA) approval for the
treatment of multiple myeloma [4], a disease that demonstrates
some similarities with PEL, such as the constitutive activation of
NF-Kappa B and STAT3. Tyrphostin AG 490, a JAK2/STAT3
inhibitor, has been also reported to induce caspase-dependent
apoptosis in PEL [5]. STAT3 is indeed constitutively activated in
this lymphoma and its growth seems to be dependent on the
STAT3 signaling [5]. Although apoptosis has been for long time
considered an apparently uniform and immunologically silent type
of cell death, it is now evident that biochemical diversity exists that
may render it immunogenic or not [6]. Diverse tumor cell type or
the same tumor cell type dying in response to different cell death
triggers can result in apoptosis that elicits a different activation of
immune response [7–8].The immunizing properties of killed
tumor cells depend on the ability of cytotoxic agents to render
their death immunogenic so that the immune system can be
specifically alerted to the presence of a tumor. The characteristics
of the immunogenic cell death are the traslocation of the
endoplasmic reticulum-resident CRT to the plasma membrane,
followed by release or surface expression of HSP70 and HSP90
molecules that either provide a direct immunogenic signal for DC
activation or act as vehicles for peptide antigen exposure [9]. The
expression on the cell surface of several chaperones has been
indicated as the most important mechanism for the activation of
the immune system and in particular of the DC [10]. In particular,
the cell surface exposure of CRT has been shown to be essential
for the uptake of dying tumor cells by DC [11], while the exposure
of HSP90 and HSP70 or their release promotes DC maturation
[12]. CRT is traslocated on the plasma membrane following
different types of endoplasmic reticulum (ER) stress stimuli
including the ER stress determined by some chemotherapeutic
agents [13]. HSP90 and HSP70 are two chaperone proteins that
are also normally localized in the intracellular compartment where
they play cytoprotective functions. Although the mechanisms
underlying their membrane traslocation are not completely clear,
it is known that their expression on the cell surface of stressed or
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cells such as Natural Killer (NK) and DC [14]. In this paper, we
compared the proteasome inhibitor Bortezomib and the JAK2/
STAT3 inhibitor tyrphostin AG 490 in triggering BC3 PEL
apoptosis and subsequently in their ability to promote the DC
maturation. Our results show that both drugs were able to induce
BC3 apoptosis and DC maturation through traslocation of CRT
and HSPs on the surface of dying cells. A previous study has
highlighted the importance of chaperone traslocation also in vivo
showing that, although displaying the same level of apoptosis or
necrosis, indolent non-Hodkgin’s lymphoma cells obtained from
patients with a good response to chemotherapy were better able to
translocate CRT and HSP90 to the cell surface than those of
nonresponders [15]. We also compared the ability of the BC3 cells
killed by these drugs to stimulate the uptake by DC and found that
Bortezomib alone induced an higher percentage of phagocytosis.
Beside the CRT and HSPs traslocation, the caspase activation
usually present in the apoptotic process is important for the
immunogenicity of the cell death [16].
The DC have a pivotal role in the eradication of apoptotic
cancer cells. These cells are able to mediate the cross-presentation
of tumor antigens to the cytotoxic T cells [17], so the DC
activation by dying tumor cells is of fundamental importance for
the outcome of cancer therapy [18]. Several receptors such as
TLR4 and 2, CD14, Lox-1 have been reported to bind the
chaperone molecules on the surface of DC [19]. Among them
CD91 that has been reported by Basu et al. as the common
receptor for HSP90, HSP70 and CRT [20]. In addition, it has
been shown that viral and tumor antigens are cross-presented by
DC through CD91pathway in patients with Kaposi sarcoma [21].
In the present study, we analyzed the effect of BC3 killed by
Bortezomib and AG 490 in inducing DC activation. Furthermore,
we evaluated if DC maturation is dependent on the exposure of
CRT and HSPs, caspase activation and CD91 expression.
Materials and Methods
Ethics statement
The study was approved by the ethical Committee of Policlinico
Umberto I, University of Rome ‘‘Sapienza’’.
Cells, reagents and antibodies
The PEL cell lines BC-3 and BCBL-1 (ATCC) were cultured in
RPMI 1640 10% Fetal Calf Serum (FCS) (Euroclone), glutamine
and antibiotics. Bortezomib (Velcade) was purchased from
Millennium Pharmaceutical Inc. (Cambridge, MA, USA) and
AG 490 was purchased from Calbiochem. Following monoclonal
antibodies were used in this study: anti CD83 (Santa Cruz,
Biotechnology incorporation), anti CD86 (BD Pharmingen), anti
CD1a-PE (BD Pharmingen), anti Calreticulin (Thermo Scientific),
anti HSP90 and anti HSP70 (Stressgen Biotech) and anti CD91
(Calbiochem).
Generation of monocyte-derived DC
To generate monocyte-derived DC, human peripheral blood
mononuclear cells, obtained from healthy donors were isolated by
Fycoll-Paque gradient centrifugation (Pharmacia, Uppsala, Swe-
den) from buffy coats. CD14+ monocytes were positively selected
using anti-CD14 MAb-conjugated magnetic microbeads (Miltenyi
Biotec, Auburn, Calif.). Purified monocytes were cultured at a
density of 1610
6 cells/3 ml in 12-well plates for 6 days in RPMI
1640 (Euroclone) containing 10% FCS, 2 mM L-glutamine,
100 U/ml penicillin G, 100 mg/ml streptomycin and recombi-
nant human granulocyte-macrophage colony stimulating factor
(GM-CSF) plus interleukin 4 (IL-4) (50 ng/ml and 20 ng/ml
respectively, Miltenyi Biotec, Auburn, Calif.).
Apoptosis assay
The effect of Bortezomib, Tyrphostin AG 490 or both was
examined after 6, 12 and 24 hours of treatments. The cells were
washed with ice-cold phosphate buffered saline (PBS), resuspended
in annexin V binding buffer (BD Pharmingen, San Diego, CA),
and subsequently stained with annexin V–fluorescein isothiocya-
nate (FITC) (BD Pharmingen) according to the manufacturer’s
recommendation. To assess the effect of the drugs on nuclear
DNA fragmentation, hypodiploic (subG1) events were determined
by cytofluorimetric analysis. Briefly, cells were washed with PBS
and fixed in ice cold ethanol/water (70/30, v/v) for 1 hour,
washed twice and resuspended in PBS, containing RNase, 40 ug/
ml, and an equal volume of PBS containing propidium iodide (PI),
100 ug/ml. Events in the different cell cycle phases were gated
manually. At least 10.000 events/sample were analysed using a
cytofluorimeter EPICS XL Coulter (Hialeah, FL), equipped with
the software ‘‘Multicycle for DNA content and cell cycle analysis’’
(Phoenix Flow System, San Diego, CA). The events in subG1,
representing the apoptotic cells, are given as percentage of the
total cell population. In the assays in which the caspase pathway
was examined, the cell-permeable caspase inhibitor carbobenzoxy-
valyl-alanyl-aspartyl (-methyl ester-fluoromethy ketone (Z-VAD-
fmk) (Calbiochem) was added at 100 mM to the cell suspension
before the induction of apoptosis.
HSPs surface expression on dying tumor cells
PEL cells were treated by Bortezomib, AG 490 or both and the
expression of surface CRT, HSP90 and HSP70 was analyzed 12 to
24 hours later by flow cytometry using specific monoclonal
antibodies.
Immunofluorescence
Untreated or treated PEL cells as described above, were fixed
with 4% paraformaldehyde in PBS for 30 min, and to investigate
CRT localization, the cells were labeled with the chicken anti
human CRT antibody (Thermo Scientific). The primary antibody
was visualized using Phycoerythrin (PE)- conjugated anti chicken
antibody.
Cells were analyzed using an Apotome Axio Observer Z1
inverted microscope (Zeiss, Oberkochen, Germany), equipped
with an AxioCam MRM Rev.3 at 406magnification.
Phagocytosis assay
The phagocytosis assay was performed as decribed previously
[22]. Briefly, apoptosis was induced in 2610
5 CFMDA-labelled
PEL cells by Bortezomib, AG 490 or both and, after washing, were
co-cultivated with 2610
5 iDCs in 24 well plates for 4 hours in
order to monitor phagocytosis. DC were labeled with anti-CD1a-
PE antibody and phagocytosis of apoptotic cells was defined by the
percentage of CFMDA-PE double positive cells by flow cytometric
analysis.
RNA interference (RNAi)
iDC were transfected with 50 pmols of CD91 siRNA or with
50 pmols of non-targeting siRNA (siCONTROL) (Santa-Cruz
Biotechnology, Inc.) using Lipofectamine RNAiMAX transfection
reagent (Invitrogen), according to the manufacture’s instructions.
The cells were incubated in a 5% CO2 incubator at 37u until they
were assayed for gene knockdown 72 hours later. Prior to use in
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FACS analysis for CD91 expression.
FACS analysis of DC phenotype after interaction with
killed tumor cells
Phenotype of DC cultured with tumor cells was monitored by
flow cytometry. Tumor cells (BC3 and BCBL1) were treated with
Bortezomib or AG 490 for 24 hours and then cocultured for
24 hours with immature DC (iDC). In some experiments, PEL
cells were not washed to monitor the drug’s side effect on DC. In
neutralizing experiments, tumor cells were coated with anti-
HSP90, anti-HSP70 and ani-CRT mAbs (10 mg/mL) or DC were
incubated with anti azide-free CD91 (10 mg/mL) before setting up
the coculture. To confirm the role of CD91 in some experiments
the DC were teated with CD91 siRNA before the coculture with
PEL. The phenotype of DC was monitored by staining with
Phycoerytrin (PE)-conjugated anti CD83 and FITC-conjugated
anti CD86 for 30 minutes at 4uC, washed twice in PBS and
analyzed on a flow cytometer. DC were gated according to their
FSC and SSC properties. Appropriate isotype controls were
included and 5000 viable DC were acquired for each experiment.
Immunoblot analysis
PEL cells treated by Bortezomib, AG 490 or both were lysed in
a lysis buffer containing 50 mM Tris HCl, pH 6.8, 10% glycerol
and 2% SDS. The lysates were then resolved by SDS-PAGE and
transferred to nitrocellulose membranes (Bio-Rad). The levels of
HSP90 and HSP70 were detected using specific antibodies. The
DC untreated or treated with CD91siRNA or with non-targeting
siRNA (siCONTROL) were lysed in the above lysis buffer,
resolved by SDS-PAGE, transferred to nitrocellulose membrane
and probed with anti-CD91 monoclonal antibody. b-actin was
also verified as loading control. The reactions were visualized by
enhanced chemiluminescence (Amersham).
Results
Bortezomib and AG 490 induce apoptosis in PEL with
similar kinetic
We first compared the effect of Bortezomib and AG 490 in BC3
PEL apoptosis. The drug concentrations used were 25 nM for
Bortezomib and 100 mM for AG 490 and were chosen according
to previous studies [3,5] and confirmed by pilot experiments (data
not shown). BC3 were treated with Bortezomib and AG 490, alone
or in combination and the induction of apoptosis was assessed by
the percentage of Annexin V positive cells after 6, 12 and 24 hours
treatment. As shown in figure 1a Bortezomib induced an higher
percentage of Annexin V positive cells in comparison to AG 490
that increased with the combination of both drugs, suggesting a
synergistic effect on BC3 apoptosis. Similar results were obtained
with BCBL1 PEL cell line (data not shown). The induction of
apoptosis was also confirmed by the appearance of an higher
percentage of events with sub G0/G1 DNA content, as mesured
by PI staining (figure 1b). Subsequently, BC3 pre-treatment with
pancaspase inhibitor Z-VAD-fmk showed reduction of Bortezo-
mib- or AG 490-induced apoptosis (figure 1c and d).
Apoptotic PEL cell lines induced DC maturation and DC
phagocytosis
Once assessed that both treatments were able to induce BC3
PEL apoptosis, we next tested the ability of live or apoptotic BC3
cells treated with Bortezomib and AG 490 to induce DC
maturation after 12 hours of coculture with immature DC
(iDC). Following this, the DC were stained with a cocktail of
mAbs and analyzed by FACS analysis for the expression of CD83
maturation marker and CD86 costimulatory molecule. DC were
gated according to their FSC and SSC properties. The exposure to
BC3 cells induced to apoptosis by Bortezomib and to a lesser
extent by AG 490 for 24 hours, resulted in a substantial up-
regulation of CD86 and a marginal increase of CD83 compared to
the exposure of iDC to the untreated BC3 cells (figure 2a). We also
verified if the same activating effect on DC could be obtained by
coculturing them with BCBL1 treated with Bortezomib, AG 490
or both. As shown in figure 2b, with this PEL cell line we obtained
a comparable effect on DC activation, as indicated by CD86 and
CD83 expression. However it is important to point out that the
DC exposed to the untreated BC3 or BCBL1 cells did show a
modest activation of DC. The combination of both drugs,
although induced an higher percent of apoptotic cells (figure 1a
and b) did not have synergistic effect on DC activation (figure 2a
and b). Interestingly, we found that Bortezomib-treated BC3 cells
exerted a toxic effect on DC that could be overcome by extensive
washes prior to the cocultures. In contrast, AG 490 treatment did
not have any toxic effect on DC (data not shown). We next
evaluated whether the DC maturation induced by BC3 cell death
was caspase-dependent. Z-VAD-fmk pre-treatment reduced drug-
induced PEL apoptosis (see above) and slightly inhibited the
activation of DC (data not shown). We finally tested the effect of
Bortezomib- and AG 490-induced BC3 PEL apoptosis on DC
phagocytic ability. To this end, dye CFMDA-labelled BC3 cells
untreated or treated with Bortezomib and AG 490 alone or in
combination were fed to immature DC (iDC). After 4 hours of
incubation, the DC were stained with anti-CD1a mAb and
analysed by FACS for the appearance of CFMDA-PE double-
positive cells, indicating phagocytosed cells. The results show an
increased phagocytosis by DC of BC3 cells killed by Bortezomib
and to a lesser extent by AG 490 or combination of both in
comparison to untreated BC3 cells (figure 2c). Altogether, these
data indicate that both Bortezomib-and AG 490-induced PEL
apoptosis triggered DC maturation, however AG 490, was less
able in inducing DC uptake of apoptotic cells.
Bortezomib and AG 490 treatments induced traslocation
of CRT, HSP90 and HSP70 on the cell surface of dying PEL
cells
To analyze the immunizing properties of dead tumor cells, we
evaluated the characteristics of the immunogenic cell death such as
the surface expression of HSP70 and HSP90 and the relocation on
the plasma membrane of the endoplasmic reticulum-resident
CRT. The expression of these molecules was evaluated by FACS
analysis after 12 and 24 hours of treatment with Bortezomib and
AG 490, alone or in combination. PEL cells showed an higher
surface expression of all molecules with Bortezomib alone or in
combination with AG 490, compared to the single treatment with
AG 490 after 12 hours (figure 3a). Moreover the percentage of
positive cells increased after longer exposure (24 hours) for all
treatments (figure 3b). Furthermore, intense CRT staining on the
plasma membrane of BC3 cells was observed by immunofluores-
cence, after 24 hours with all the above treatments (figure 3c). We
next evaluated whether caspase-dependent BC3 PEL cell
apoptosis was involved in CRT, HSP90 and HSP70 surface
translocation. Interestingly, Z-VAD-fmk pre-treatment, although
reduced BC3 apoptosis (see above), did not impair the surface
traslocation of CRT and HSP90, while reduced HSP70 surface
expression (figure 3d). We next evaluated the total expression of
HSP90 and HSP70 in BC3 cells treated with Bortezomib and AG
490 alone or in combination for 24 hours by immunoblotting. As
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drug treatments. On the contrary, Bortezomib alone increased the
expression of HSP70 (figure 3f).
Inhibition of DC maturation by blocking CD91, CRT,
HSP90 and HSP70
We finally investigated the role of CRT and HSPs in the
induction of DC maturation. To this end, BC3 treated with
Bortezomib and AG 490 were coated with neutralizing antibodies
directed against these molecules before coculturing with iDC. We
found only a partial reduction in DC maturation, as assessed by
CD83/CD86 staining, when a cocktail of antibodies for CRT,
HSP90 and HSP70 was used (figure 4b) whereas the antibody
directed against each single molecule did not have any inhibiting
effect (data not shown). Although several molecules have been
reported to act as receptors for HSPs or for HSP-peptide antigen
complexes on the surface of DC, we observed a complete
inhibition of DC maturation by using a neutralizing antibody
directed against CD91, also known as LRP1, a common receptor
for CRT, HSP90 and 70 (figure 4c). Altogether, these data
Figure 1. Bortezomib and AG 490 induce apoptosis in BC3 PEL cell line. PEL cells were exposed to Bortezomib, AG 490 or both for the
indicated times, then resuspended in Annexin V binding buffer and stained with Annexin V (a). The effect of the drugs was also evaluated on nuclear
fragmentation (sub-G0/G1 phase) that represent the apoptotic cells. Cells were fixed in ethanol/water (70/30, vol/vol), washed in PBS containing
RNAse and then stained with Propidium Iodide (PI) (b). The analysis was performed by flow cytometry. The reduction of the percentage of Annexin V
positive (c) or the sub-G0/G1 cells (d), obtained with Z-VAD-fmk pre-treatment at 100 mM, is also shown. The experiments were performed
simultaneously with 1a and 1b at 24 hours. Mean plus SD is indicated.
doi:10.1371/journal.pone.0031732.g001
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PEL BC3 surface of CRT, HSP90 and HSP70 and that DC
maturation is mediated by the interaction of these molecules with
CD91. To confirm the role of CD91 in the DC activation
mediated by killed PEL we used RNAi to knockdown CD91
protein expression in human DC. To evaluate the silencing
efficiency of CD91 we performed an immunoblot 72 hours after
trasfection and as shown in figure 4d the CD91 expression was
reduced respect to the control treated only with transfection
reagent while the expression of control protein b-actin was
unaffected. The flow cytometric analysis of CD91 siRNA
displayed similar results (figure 4e). We next addressed the
question of whether the knockdown of CD91 on DC had a
negative effect on their activation after coculture with killed BC3
and as shown in figure 4f DC treated with CD91 siRNA displayed
a reduction of the CD86 and CD83 markers. These results
confirm the pivotal role of CD91 in the DC activation mediated by
killed PEL.
Discussion
Bortezomib has been shown to induce immunogenic cell death
in solid tumors [22], in multiple myeloma due to the surface
exposure of HSP90 [14] and to induce apoptosis in PEL [3].
Tyrphostin AG 490 has been also reported to induce apoptosis in
PEL by inhibiting its constitutive STAT3 activation [5]. Here we
asked if the Bortezomib- and AG 490-induced PEL cell death
could be immunogenic. The immunogenicity of drugs-induced cell
death was evaluated in terms of DC activation and maturation
since DC have a pivotal role in the eradication of apoptotic cancer
cells by mediating the cross-presentation of tumor antigens to the
cytotoxic T cells, initiating a specific immune response [16]. For
these reasons the DC activation by dying tumor cells is of
fundamental importance for the outcome of cancer therapy [17].
The results shown in this paper demonstrate that Bortezomib and
AG 490 induced apoptotic cell death in BC3 PEL with similar
kinetic and that dying cells exposed CRT, HSP90 and HSP70 on
the cell surface promoting uptake by DC and DC maturation.
However, Bortezomib was more effective than AG 490 in inducing
the expression of the above molecules and in inducing the DC
uptake.
Apoptosis can have different impact on the immune system [6].
It is reported that apoptosis occurring during physiological tissue
turnover does not result in the immune activation, however
apoptosis can be immunogenic when induced by some cytotoxic
agents [23]. Combining the killing effect of chemotherapies with
the activation of immune response and in particular with DC
activation is fundamental to improve the survival of cancer
patients. Here we found that the drugs-induced BC3 cell death
could be reduced by pre-treatment with pancaspase inhibitor Z-
VAD-fmk. This is consistent with the finding that both drugs were
able to induce apoptosis. Interestingly, the reduction of apoptosis
by Z-VAD-fmk did not inhibit the maturation of DC, suggesting
additional mechanisms other than caspase activation for triggering
DC activation by the killed BC3 PEL cells. Essential for the
immunogenicity of cell death seems to be the exposure of CRT,
Figure 2. Effect of apoptotic BC3 and BCBL1 cells on DC. CD83 and CD86 expression was verified by FACS analysis as indicator of DC
maturation induced with BC3 cells (a) and BCBL1 (b) treated with Bortezomib, AG 490 or both for 24 hours and cocultured with iDC for 12 hours.
Staining with isotype control (filled histograms) is also shown. Phagocytosis of Bortezomib and AG 490 treated BC3 cells (stained with CFMDA-green)
by DC (stained with anti-CD1a/PE-red) in a four hour assay. The phagocytosis of apoptotic cells is indicated by the percentage of CFMDA-PE double
positive cells by flow cytometric analysis (c). Results are representative of three independent experiments.
doi:10.1371/journal.pone.0031732.g002
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molecules are usually located in the intracellular compartment
where they regulate Ca2+ homeostasis (CRT) or have cytopro-
tective function (HSP90 and HSP70). When translocated on the
cell surface they act as ‘damage-associated molecular patterns’
(DAMPs) and acquire immunostimulatory properties [6]. The
membrane traslocation of CRT has been linked to ER stress and
in particular to the PERK/eIF2a arm of the unfolded protein
response (UPR) pathway. When exposed on the cell surface, CRT
is a crucial determinant of the phagocytosis of tumor cells dying an
apoptotic cell death and in the initiating a tumor-direct immune
response [24,25]. HSP90 and HSP70 are overexpressed in a
‘stressful environment’ such as tumor environment and under
stress they can also translocate to the plasma membrane even if it
is not clear through which mechanism [20,26]. In agreement with
these findings, we found that Bortezomib and AG 490 induced
DC maturation through relocalization on PEL surface of CRT,
HSP90 and HSP70.
These molecules, exposed on the plasma membrane of the
stressed or dying cells, can interact with a number of receptors
present on the DC surface that receive a direct activating signal or
mediated by the HSP-peptide antigen complexes. Among them
are Toll-like receptor 4 and 2, CD14, CD40, Lox-1 and CD91.
The latter has an important role in the binding of CRT [27], HSPs
[28] and has a foundament importance in the uptake and cross-
presentation of chaperone-bound viral or tumor antigens [21].
Here we found that DC maturation obtained by cocultivating
them with apopotic PEL BC3 cells was completely abolished by
neutralizing CD91 receptor with a specific mAb antibody. The
involvement of CD91 was further assessed by RNA interference
showing strong reduction of DC maturation after CD91
knockdown. The importance of this molecule in the immune
response has been underlied by the observation that CD91
represent an important route for stimulating a CD8
+ T-cell
response by MHC class I-restricted presentation [21]. Moreover,
CD91 is the only molecule upregulated on the surface of DC in
HIV-infected patients with no evidence of progressive disease for
more than 10 years while remaining off treatment, termed ‘‘long-
term nonprogressors’’ [29,30]. Upregulation of CD91 in cancer
patients may represent an additional strategy to improve DC
activation and subsequent stimulation of a specific CD8
+ T cell
response towards tumor cells dying an immunogenic cell death. In
Figure 3. Bortezomib and AG 490 induce immunogenic BC3 cell death. Induction of HSP90, CRT and HSP70 traslocation on BC3 cell surface
induced by Bortezomib, AG 490 or both after 12 hours (a) or 24 hours (b) treatments was evaluated by flow cytometric analysis. Mean of the
percentage of positive cells plus SD of three independent experiments is indicated. Plasma membrane localization of CRT after Bortezomib, AG 490 or
Bortezomib plus AG 490 treatments was also analyzed by immunofluorescence on BC3 fixed with 4% paraformaldehyde in PBS for 30 min and the
arrows indicate the presence of CRT on the surface of the cells (c). One representative experiment out of three is shown. The effect of Z-VAD-fmk pre-
treatment (100 mM) before exposure to Bortezomib and AG 490 on HSP90, CRT and HSP70 surface expression was evaluated by flow cytometric
analysis. Mean of percentage of positive cells plus SD of three independent experiments is indicated (d). Western blot analysis showing the total
HSP90 and 70 expression after 24 hours treatment of BC3 with Bortezomib, AG 490 or both (e–f). Results are representative of two independent
experiments.
doi:10.1371/journal.pone.0031732.g003
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e31732Figure 4. Inhibition of immunogenicity of Bortezomib and AG 490 killed BC3 PEL cells. DC activation obtained by coculture with BC3 cells
untreated or killed by Bortezomib or AG 490 (a) or with killed BC3 coated with neutralizing antibody cocktail directed against HSP90, 70 and CRT
before starting the coculture with iDC (b) or iDC coated with anti-CD91 mAb before starting the coculture with killed BC3 (c). Results are
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PEL apoptosis and that apoptotic BC3 triggered DC maturation
and phagocytosis. It is important to consider, though, that
Bortezomib, if not extensively washed out before BC3 coculture
with DC, had toxic effect on DC. This is consistent with previously
reported studies [31]. On the contrary, AG 490 did not have any
side effect on DC viability or function, suggesting a more risk-free
use of AG 490 for systemic administation in cancer patients.
Moreover, as STAT3 is hyperphosphorylated in DC in the tumor
environment or exposed to the tumor supernatants [32,33],
leading to DC dysfunction, the use of AG 490 has been shown to
be able to revert their dysfunction [34]. On the other hand,
Bortezomib could be more indicated for target delivery to the
tumor, such as by coupling it with tumor specific mAbs. Finally we
observed that, although Bortezomib and AG 490 synergized in
inducing BC3 PEL cell death, their combination did not result in a
better activation of DC and this observation warrants caution in
cancer therapies combining both molecules, already in clinical
trials for some tumors [35].
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representative of three independent experiments. The staining with isotype control (filled histograms) is also shown. Reduction of CD91 expression
by RNAi on DC was evaluated after 72 hours by Immunoblotting (d) and by FACS analysis (black empty hystogram in comparison with gray empty
hystogram) (e). The effect of CD91 knockdown on the DC activation mediated by coculture with Bortezomib-killed BC3 cells (black empty histograms)
in comparison with the control DC (gray empty histograms) (f). The staining with isotype antibody only (filled histograms) is also shown. Results are
representative of three independent experiments.
doi:10.1371/journal.pone.0031732.g004
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